Sign in
CompletedNo phase

Esketamine on Postpartum Depression in Cesarean Section Women

Key facts

Who runs it
Ailin Luo
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
336 people enrolled
Started
1 May 2021
Ended
31 Mar 2024
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Esketamine
  • Normal saline
Record updated
6 August 2024

Who can take part

Age
18 years to 40 years
Sex
Women only
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 17 criteriaShow less

Who can take part

  • Elective cesarean section
  • 18-40 years
  • Primipara
  • Singleton pregnancy
  • Sign informed consent

Who cannot take part

  • Drug abuse and alcoholism
  • Intracranial hypertension
  • Hypertension
  • Severe heart disease
  • Mental disorder, mental retardation
  • American Society of Anesthesiologists (ASA) grade III and above
  • Hyperthyroidism patients without treatment or insufficient treatment
  • Liver and kidney dysfunction
  • Preeclampsia or eclampsia
  • Contraindication of intraspinal anesthesia
  • The preoperative EPDS score ≥10
  • Participated in other clinical studies

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study was to explore the preventive effect of esketamine on postpartum depression (PPD) in cesarean section, and to evaluate the safety of the drug

The 2 groups in the trial

  • N groupPlacebo, for comparison

    15 minutes after umbilical cord amputation, the patient was intravenously injected with 10 ml normal saline

    Treatment: Normal saline

  • Es groupTreatment being tested

    15 minutes after umbilical cord amputation, the patient was intravenously injected with 0.25mg/kg esketamine, PCIA regimen: sufentanil 100 μ g, esketamine 80 mg, diluted to 100 ml with 0.9% normal saline, set analgesia pump background infusion dose 2 ml/h, single bolus dose 2 ml, locking time 8 minutes.

    Treatment: Esketamine

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Effect of Prophylactic Esketamine on Postpartum Depression in Cesarean Section: A Multicenter, Prospective, Randomized, Controlled Study
Publications
Record updated
6 August 2024